How the testing is bogus





1) Here is the Steere original report in which he remarks that Lyme is
like the trypanosomes:
http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=3531237

Although he says that data was not available on the serology of
Relapsing Fever, there actually was such data:
http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=3540570
This second article is a very comprehensive article and you should read
it about three times. In it you will find that rodent brains were the
storage media and that the bug sheds (blebbing) surface antigens
(flak).

2) The second example of the clarity in which it was understood that
Lyme was a relapsing fever borreliosis and changed surface antigens,
necessitating serial Western Blots is this CDC document from 1990:
http://www.actionlyme.org/CDC_DOCUMENTS_1990.htm
"Significant change in IgM and IgG antibodies..." in serial Western
Blots. (Page 20 of that CDC publication.)

3) Dattwyler and Luft at the FDA in June 1994, suggest that the way to
test for Lyme is to do serial Western Blots:
http://www.actionlyme.org/Dattwyler_Luft_Bb_DNA_in_CSF.htm
See where I circled what he said.

====

The Igenex Paper, where Nick Harris says about what I said to the FDA 3
years later:
http://www.igenex.com/labtest.htm
http://www.fda.gov/ohrms/dockets/ac/01/slides/3680s2_11.pdf
--------------

Click on page 3533 here:
http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=1894359
Fikrig picked a fragment of Borrelia flagellin which resulted in a
protein, against which only Lyme victims' band 41 reacted.
That made the test SPECIFIC (an FDA rule) to the diagnosis of LYME, and
not some other infection that had produced an anti-flagellar antibody.

One of the rules of a method validation is SPECIFICITY, or that, the
test does not detect something else, with some degree of certainty.

Here is that patent, in which Yale makes the identical claims of
validity to the US Patent Office:
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5,618,533.PN.&OS=PN/5,618,533&RS=PN/5,618,533

"Infection with B. burgdorferi induces a strong humoral immune
response. *Early* in human infection, antibodies are generated
primarily against the 41-kDa flagellar protein. In later stages,
antibodies to the outer surface proteins OspA and OspB, among others,
appear [J. E. Craft et al., "Antigens Of Borrelia burgdorferi
Recognized During Lyme Disease", J. Clin. Invest., 78, pp. 934-39
(1986)]. .."

========

NOW ON TO ALAN BARBOUR SAYING NUMEROUS STRAINS OF BUGS SHED NUMEROUS
TYPES OF ANTIGENS, AND THAT AS A RESULT, THE IMMUNE SYSTEM MAY BE
COMPLETELY OVERWHELMED (which means the current testing for Lyme is
bogus)

http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=5&f=G&l=50&co1=AND&d=PTXT&s1=barbour.INNM.&s2=borrelia.ABTX.&OS=IN/barbour+AND+ABST/borrelia&RS=IN/barbour+AND+ABST/borrelia

"2.1 Methods of Treatment

"An important aspect of the invention is the recognition that Borrelia
VMP-like sequences recombine at the vls site, with the result that
antigenic variation is virtually limitless. Multiclonal populations
therefore can exist in an infected patient so that immunological
defenses are severely tested if not totally overwhelmed.

"Thus there is now the opportunity to develop more effective
combinations of immunogens for protection against Borrelia infections
or as preventive inoculations such as in the form of cocktails of
multiple antigenic variants based on a base series of combinatorial
VMP-like antigens. "

------

All of that means that they only test we can use for all kinds of Lyme
is a borrelia-specific flagellin antibody test, since flagellin does
not change. It is not a varying antigen.

__._,_.___

.



Relevant Pages